A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma
Clinical trial NCT04831658 · UNKNOWN
Trial details
- NCT number
- NCT04831658
- Sponsor
- Mingzhi Zhang
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-29
- Primary completion
- 2023-09-15
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.